ADC Biotechnology (ADC Bio) predicts that the next crucial phase of innovation to optimise and streamline production processes of ADCs will be designed at the clinical development stage by specialist, ADC focused service providers.

IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few contract development and manufacturing organisations (CDMO) to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.

The Johnson & Johnson Human Performance Institute today announced it is expanding its footprint in the Lake Nona community in Orlando, Florida with the construction of its new global headquarters.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq.

ADC Biotechnology (ADC Bio) announces that it is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing.